Please assess the completion status of the following clinical trial:

Trial Title: A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary or secondary renal allograft within preceding 14 days;~* IgG seropositive for CMV;~* receiving immunosuppressive therapy.~Exclusion Criteria:~* active CMV infection;~* current/history of malignancy;~* acute steroid resistant rejection episode since transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valganciclovir Cytomegalovirus (CMV) Prophylaxis (Type: EXPERIMENTAL): None
- Pre-emptive CMV Therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).